An unsupervised learning approach for clustering joint trajectories of Alzheimer's disease biomarkers: An application to ADNI Data.

Introduction: Current models of Alzheimer's disease (AD) progression assume a common pattern and pathology, oversimplifying the heterogeneity of clinical AD.

Methods: We define a syndrome as a unique biomarker progression pattern and develop a lag measure to cluster pre-dementia individuals, reflecting their pathology's multi-dimensionality. The technique uses the time-ordering of events to group individuals based on their position along the disease process and the relative positions of their markers.

Structural and Functional Glycosylation of the Abdala COVID-19 Vaccine.

Abdala is a COVID-19 vaccine produced in Pichia pastoris and is based on the receptor-binding domain (RBD) of the SARS-CoV-2 spike. Abdala is currently approved for use in multiple countries with clinical trials confirming its safety and efficacy in preventing severe illness and death. Although P.

Inhibition of pterygium cell fibrosis by the Rho kinase inhibitor.

Pterygium is an ocular disease in which the conjunctival tissue invades the cornea. When the pterygium tissue reaches the pupillary region, the visual function of the patient is affected. Currently, surgical removal is the only effective treatment.

Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.

The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in standardizing and validating amyloid beta (Aβ) and tau positron emission tomography (PET) imaging. ADNI data were used for the US Food and Drug Administration (FDA) approval of the Fujirebio and Roche Elecsys cerebrospinal fluid diagnostic tests.